Revance Therapeutics reported $-61435000 in Pre-Tax Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Cara Therapeutics CARA:US $ -4206000 23.54M
Coherus Biosciences CHRS:US $ -50.15M 45.93M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Revance Therapeutics RVNC:US $ -61.44M 2.91M
Supernus Pharmaceuticals SUPN:US $ 11.32M 3.4M